Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …

Due to the unpredictable course and heterogenous treatment response in multiple sclerosis
(MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up …

Objective Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the
cerebrospinal fluid (CSF), and are detectable at low concentrations in peripheral blood …

Background/objectives: Neurofilament light chain (NfL) levels in the cerebrospinal fluid
(CSF) of multiple sclerosis (MS) patients correlate with the degree of neuronal injury. To …

Despite improved understanding of the pathogenesis of neuroinflammatory disorders of the
brain and development of new diagnostic markers, our biomarker repertoire to demonstrate …

There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive
disability. The development of treatments may be accelerated if novel biomarkers are …

Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune disease with a complex
clinical course characterized by inflammation, demyelination, and axonal degeneration …

Cerebrospinal fluid (CSF) biomarkers can reflect different aspects of the pathophysiology of
relapsing‐remitting multiple sclerosis (RRMS). Understanding the impact of different disease …

The knowledge of inflammation records dates back in first century AD. Initially discovered
with features of rubor, tumor, calor, and dolor, scientific investigations have revealed …

Background: Cerebrospinal fluid (CSF) biomarkers have been suggested to predict multiple
sclerosis (MS) after clinically isolated syndromes, but studies investigating long-term …